Sugi Predict

Sugi Predict / Compounds / SCHEMBL19851187

SCHEMBL19851187

SCHEMBL19851187

CN1CCN(Cc2ccccc2)C2(CNC2=O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 1/20 0.43
▸ OPRL1 P41146 2/20 0.42
▸ OPRM1 P35372 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ OPRK1 P41145 1/20 0.42
▸ SLC6A9 P48067 2/20 0.41
▸ GAA P10253 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ GSK3A P49840 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ CCR5 P51681 4/20 0.37
▸ SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19839185 1.00 MC4R (0.43) MC4ROPRL1OPRM1OPRD1OPRK1
SCHEMBL19851211 0.88 OPRL1 (0.44) MC4ROPRL1OPRM1OPRD1OPRK1
SCHEMBL19851178 0.85 OPRL1 (0.49) MC4ROPRL1OPRM1OPRD1OPRK1
SCHEMBL19839177 0.85 OPRL1 (0.49) MC4ROPRL1OPRM1OPRD1OPRK1
SCHEMBL19839200 0.81 SIGMAR1 (0.45) OPRL1OPRM1OPRD1OPRK1SLC6A9
SCHEMBL19851191 0.81 SIGMAR1 (0.45) OPRL1OPRM1OPRD1OPRK1SLC6A9
SCHEMBL26426361 0.80 MC4R (0.44) MC4ROPRM1GAAKDM4ETP53
SCHEMBL25764397 0.78 SLC6A9 (0.47) OPRL1OPRM1OPRD1OPRK1SLC6A9
SCHEMBL26426429 0.77 CHRM1 (0.40) OPRL1OPRM1OPRD1OPRK1SLC6A9
SCHEMBL19839167 0.75 CHRM1 (0.39) OPRL1OPRM1OPRD1OPRK1SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3490993-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2023-12-06 — — EP disclosed
US-20230210851-A1 SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME APTINYX INC (US) 2023-07-06 — — US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 — — US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 — — US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 — — US disclosed
US-11376250-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2022-07-05 — — US disclosed
US-11376250-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2022-07-05 — — US disclosed
CN-109890825-B Spiro-lactam NMDA receptor modulators and uses thereof 阿普廷伊克斯股份有限公司 2022-03-11 — — CN disclosed
US-20210322406-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2021-10-21 — — US disclosed
US-20210322406-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2021-10-21 — — US disclosed
US-10918637-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-02-16 — — US disclosed
US-10918637-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-02-16 — — US disclosed
US-20190175588-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2019-06-13 — — US disclosed
US-20190175588-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2019-06-13 — — US disclosed
WO-2018026782-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376250-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A MC4R 619/4885OPRL1 27/4885OPRM1 35/4885
US-20190175588-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A MC4R 619/4885OPRL1 27/4885OPRM1 35/4885
US-20210322406-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A MC4R 619/4885OPRL1 27/4885OPRM1 35/4885
US-10918637-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A MC4R 619/4885OPRL1 27/4885OPRM1 35/4885
US-20230210851-A1 SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME ACE, ACE2, PREP MC4R 4117/4885OPRL1 1783/4885OPRM1 2893/4885
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A MC4R 619/4885OPRL1 27/4885OPRM1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.